# Semaglutide 2.4 mg Cost-Effectiveness in Japan: A Lifetime Model With Retreatment

A lifetime Markov model put semaglutide 2.4 mg at ¥5,300,580 per QALY in Japan without diabetes and ¥7,077,984 with it, with retreatment after a mandated break driving the gains.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/the-model-only-works-if-you-go-back-on-it
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Semaglutide 2.4 mg Cost-Effectiveness in Japan: A Lifetime Model With Retreatment

A lifetime Markov model put semaglutide 2.4 mg at ¥5,300,580 per quality-adjusted life year in Japan without type 2 diabetes. Modeled gains improved substantially when patients could restart after a capped course.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

Modeled cost per quality-adjusted life year · obesity, no type 2 diabetes · ¥5,300,580 · obesity with type 2 diabetes · ¥7,077,984 · A simulation, not an observation. · The figures improve only if retreatment is allowed.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A lifetime Markov model estimated the cost-effectiveness of semaglutide 2.4 mg in Japan from a public payer perspective, discounted at 2%.
-   The modeled cost per quality-adjusted life year was ¥5,300,580 without type 2 diabetes and ¥7,077,984 with it.
-   Japan's Optimal Use Promotion Guidelines cap treatment duration, so the model tested zero, one or two retreatment courses with a one-year gap after each.
-   Allowing retreatment improved the modeled QALY gains substantially. Everything here is a simulation, not a measurement.

As in the [semaglutide cost-effectiveness analysis for MASH](https://buythisglp.com/research/is-semaglutide-cost-effective-for-mash), this study uses a model to project costs and quality-adjusted life years. It follows a hypothetical cohort through simulated health states over decades. Novo Nordisk Pharma funded the study and manuscript, and two authors were company employees [\[1\]](https://buythisglp.com/research/the-model-only-works-if-you-go-back-on-it#ref-1).

With that established, the interesting part is not the headline ratio. It is what the model had to assume to get there. Japan’s Optimal Use Promotion Guidelines restrict who is eligible for semaglutide 2.4 mg and cap how long they can stay on it. So the authors modeled zero, one or two retreatment courses, with a fixed one-year off-treatment period after each regimen. The two published ratios differ by approximately 1.34-fold. The model estimated a higher ratio in the cohort with type 2 diabetes.

The value case rests on going back on the drug

Allowing retreatment increased projected quality-adjusted life years. The result depends on assumptions about what happens during the break and how well treatment works after restarting. The [GLP-1 prepayment guide](https://buythisglp.com/research/should-you-prepay-for-a-glp1) addresses a separate question about what happens to an upfront payment when treatment ends early.

The modeled population was people with a BMI of 35 or more plus at least one obesity-related comorbidity, or a BMI of 27 or more plus at least two obesity-related disorders. The intervention was semaglutide 2.4 mg with diet and exercise, against diet and exercise alone. Our [comparison of liraglutide and semaglutide](https://buythisglp.com/research/is-liraglutide-as-good-as-semaglutide) discusses a separate model with its own prices and assumptions. Complication costs in this model came from Japanese sources.

On that point, this desk will not convert the yen figure to dollars. A cost-effectiveness ratio is only meaningful against the willingness-to-pay threshold of the system that produced it, and Japan’s threshold, prices and complication costs are its own. An exchange rate applied to a health-economic ratio produces a number that looks informative and is not.

The authors flag the uncertainties themselves: retreatment efficacy and long-term discontinuation are the weak joints in the model, and both are exactly the places where real data is thin. The article on [semaglutide dosing in clinical practice](https://buythisglp.com/research/what-semaglutide-dose-do-people-stay-on) describes what one clinic observed during treatment. Those observations provide context for real-world dosing and do not establish how often patients restart after a treatment cap.

## Frequently asked

What did the model conclude?

A cost per quality-adjusted life year of ¥5,300,580 for obesity without type 2 diabetes and ¥7,077,984 with it, from a Japanese public payer perspective discounted at 2%.

Why does retreatment matter so much?

Japan's guidelines cap treatment duration, so the model tested zero, one or two further courses after a one-year gap. Allowing retreatment substantially improved the modeled gains.

Does this tell me what semaglutide is worth where I live?

No. A cost-effectiveness ratio only means something against the willingness-to-pay threshold, prices and complication costs of the system that produced it.

## Sources

1.  \[1\] Kamada Y, Wada S, Matsuda H, Dai Y (2026). Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios Journal of Health Economics and Outcomes Research. [PMID 42394652](https://pubmed.ncbi.nlm.nih.gov/42394652/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
